Clinical trials: Double-blind Randomized Controlled Study
Osteopathic Manipulative Treatment
Osteopathic Sympathetic Harmonization and Depression
Depression appears to be resistant to the available pharmacological treatments. Autonomic responses accompanied by any psychological stress are sympathetic nervous system (SNS) and neuroendocrine responses are formed by…
- Trial name
- NCT04840043
- Testing
- Osteopathic sympathic harmonization
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Cumhuriyet University
Developmental and Epileptic Encephalopathy (DEE)
A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC).
- Trial name
- NCT07723976
- Testing
- CBD-OS
- Volunteers
- 120 people
- Sponsor
- Jazz Pharmaceuticals
Type 1 Diabetes (T1D)
PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study
This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with…
- Trial name
- PRISE-hATG (NCT07670650)
- Testing
- SAB-142
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of Florida
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation…
- Trial name
- TRANSPORT (NCT01807949)
- Testing
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 563 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Allergic Rhinitis
Sublingual Immunotherapy in Children With Allergic Rhinitis
The purpose of this study is to evaluate the clinical efficacy and mucosal/systemic antibody response changes after SLIT using house dust mite allergen with or without bacterial extracts in mite-allergic children.
- Trial name
- SLIT (NCT01506843)
- Where
- Brazil
- Volunteers
- 122 people
- Sponsor
- Federal University of Uberlandia
Sevoflurane Agitiion in Pediatric
Comparing the Synergistic Effect of Caudal Dexmedetomidine and Propofol Versus Caudal Dexmedetomidine Only or Propofol Only in Prevention of Sevoflurane Related Emergence Agitation in Pediatric Patients Undergoing Congenital Inguinal Hernia Repair
evaluate the synergistic efficacy of propofol and caudal dexmedetomidine for postoperative EA in pediatrics aged from to 2 to 5 years maintained on sevoflurane inhalational anesthesia and scheduled for conginital inguinal hernia…
- Trial name
- NCT06734195
- Testing
- dexmedetomidine + propofol, Propofol alone, Dexmedetomidine
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Otitis Media, Suppurative
Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry
The purpose of the study is to assess the efficacy of amoxicillin-clavulanate in treating acute otitis media in children. The primary end point is time to disappearance of middle ear effusion which monitored by daily tympanometry…
- Trial name
- NCT01244581
- Testing
- Amoxicillin-clavulanate
- Where
- 2 sites in Finland
- Volunteers
- 84 people
- Sponsor
- University of Oulu
Generalized Myasthenia Gravis
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT04963270
- Testing
- Satralizumab
- Where
- 76 sites in United States, Argentina and 15 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Acne Vulgaris
A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%
The purpose of this study is to compare the safety and efficacy of 5% Dapsone Topical Gel, (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%.
- Trial name
- NCT00151541
- Testing
- Dapsone Topical Gel + adapalene gel 0.1%, Dapsone Topical Gel + benzoyl peroxide gel 4%, Dapsone Topical Gel + vehicle control
- Volunteers
- 301 people
- Sponsor
- Allergan
Atopic Dermatitis
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.
- Trial name
- NCT04605094
- Testing
- Benralizumab
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 194 people
- Sponsor
- AstraZeneca
Irritability Associated With Autism Spectrum Disorder
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
- Trial name
- NCT07284745
- Testing
- KarXT, KarX-EC
- Where
- 39 sites in United States, Australia and 2 more
- Volunteers
- 176 people
- Sponsor
- Bristol-Myers Squibb
ADHD
AR08 for Treatment of ADHD in Children
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio.
- Trial name
- NCT01876719
- Testing
- AR08
- Where
- 13 sites in United States
- Volunteers
- 122 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Tarui Disease, Debrancher Deficiency
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses
The aim of this study is to investigate the effect of 14 days of treatment with the dietary oil-supplement Triheptanoin on fat metabolism and exercise tolerance in patients with Phosphofructokinase deficiency, Debrancher…
- Conditions
- Tarui Disease, Debrancher Deficiency, GYG1 DEFICIENCY
- Trial name
- NCT03642860
- Testing
- Triheptanoin
- Where
- Denmark
- Volunteers
- 3 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Niemann-Pick Disease, Type C1
Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1
A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann Pick disease type C1 (NPC1).
- Trial name
- TransportNPC (NCT04860960)
- Testing
- Hydroxypropyl-beta-cyclodextrin
- Where
- 35 sites in United States, Argentina and 11 more
- Volunteers
- 94 people
- Sponsor
- Cyclo Therapeutics, Inc.
Diarrhea
Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old
This study will be a Phase I, randomized, double blind, safety and immunogenicity trial of the Vero cell based 116E neonatal rotavirus vaccine candidate strain in healthy non-malnourished infants aged 8-20 weeks at three…
- Trial name
- NCT00439660
- Testing
- Oral Rotavirus Vaccine 116E Live Attenuated
- Where
- India
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Acute Kidney Injury
Ciclosporin to Protect Renal Function In Cardiac Surgery
The purpose of this study is to evaluate the potential of ciclosporin in reducing risk and degree of acute kidney injury after cardiac surgery.
- Trial name
- CiPRICS (NCT02397213)
- Testing
- Ciclosporin
- Where
- Sweden
- Volunteers
- 155 people
- Sponsor
- Region Skane
Acute Vaso Occlusive Crisis (VOC)
L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)
The purpose of this study is to determine if intravenous L-citrulline can abrogate an active vaso-occlusive crisis in sickle cell disease, resulting in decreased pain, reduction or elimination of opiate usage, and reduction or…
- Trial name
- NCT04852172
- Testing
- L-citrulline, D5 1/2NS
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
The KHENERGYC Study
This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of…
- Conditions
- Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, MELAS, Subacute Necrotizing Encephalomyelopathy
- Trial name
- NCT04846036
- Testing
- Sonlicromanol
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Khondrion BV
Acne Vulgaris
P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.
- Trial name
- NCT02667444
- Testing
- SB204 4%, Vehicle Gel
- Where
- 55 sites in United States
- Volunteers
- 1,330 people
- Sponsor
- Novan, Inc.
Impetigo
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
This study will be a multicenter, randomized, vehicle controlled, parallel, group, double blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to one of four treatment groups: 1.5% CD07223…
- Trial name
- NCT01670032
- Testing
- Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID
- Where
- 13 sites in United States, South Africa
- Volunteers
- 328 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.